Bayer partners with Chong Kun Dang to sell Kerendia
By Nho, Byung Chul | translator Kim, Jung-Ju
24.02.06 05:50:43
가나다라
0
Signed a co-promotion agreement with Chong Kun Dang… receives attention as a primary treatment for early chronic kidney disease
HK Inno.N’s Kremezin and Daewon’s Renamezin have formed a KRW 20 billion market
Chong Kun Dang’s sales and marketing ability put to the test… Kerendia receives attention as the dark horse
An upturn is expected in the KRW 20 billion markets for chronic kidney disease treatments, with Bayer and Chong Kun Dang joining forces to establish a joint sales front for its chronic kidney disease treatment, Kerendia Tab,
According to industry sources, Bayer and Chong Kun Dang signed a joint sales agreement for Kerendia Tab today (February 6) and will challenge the market as a ‘first-line treatment’ for chronic kidney disease.
Bayer's innovative new drug Kerendia Tab. 10-20mg (finerenone) was approved by the Ministry of Food and Drug Safety in April 2022 for indications including as chronic kidney disease and was listed for reimbursement on the 1st of this month. The drug pr
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)